Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Melero

Showing results (181-190 of 332) with videos related to

Pageof 34
Sort By:
NPJ Digital Medicine|March 24, 2023
Weakly supervised deep learning to predict recurrence in low-grade endometrial cancer from multiplexed immunofluorescence imagesDaniel Jiménez-Sánchez, Álvaro López-Janeiro, María Villalba-Esparza, et al.
Immunobiology|June 22, 2026
Monomethyl-auristatin E-based anti-CD137 (4-1BB) antibody drug conjugates are not suitable tools to deplete activated T lymphocytesGabriel Gomis, Saioa Arrieta-Aranzueque, Claudia Herrero, et al.
European Journal of Immunology|January 18, 2008
IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosisIvan Martinez-Forero, Ricardo Garcia-Munoz, Sara Martinez-Pasamar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myelomaOihana Murillo, Ainhoa Arina, Sandra Hervas-Stubbs, et al.
Plos One|January 4, 2013
Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapyMaria C Ochoa, Jessica Fioravanti, Erwin H Duitman, et al.
BMJ Oncology|February 25, 2026
First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumoursCarlos Gomez-Roca, Stéphane Champiat, Francois-Xavier Danlos, et al.
EMBO Molecular Medicine|November 21, 2019
Repurposing the yellow fever vaccine for intratumoral immunotherapyMaria Angela Aznar, Carmen Molina, Alvaro Teijeira, et al.
Cancer Discovery|October 24, 2015
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic CellsAlfonso R Sánchez-Paulete, Francisco J Cueto, María Martínez-López, et al.
Oncoimmunology|January 4, 2018
Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB)Arantza Azpilikueta, Elixabet Bolaños, Valerie Lang, et al.
Journal for Immunotherapy of Cancer|January 16, 2026
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumorsIgnacio Melero, Neeltje Steeghs, Ulrik Lassen, et al.
Pageof 34

Showing results (181-190 of 332) with videos related to

Sort By:
Pageof 34
NPJ Digital Medicine|March 24, 2023
Weakly supervised deep learning to predict recurrence in low-grade endometrial cancer from multiplexed immunofluorescence imagesDaniel Jiménez-Sánchez, Álvaro López-Janeiro, María Villalba-Esparza, et al.
Immunobiology|June 22, 2026
Monomethyl-auristatin E-based anti-CD137 (4-1BB) antibody drug conjugates are not suitable tools to deplete activated T lymphocytesGabriel Gomis, Saioa Arrieta-Aranzueque, Claudia Herrero, et al.
European Journal of Immunology|January 18, 2008
IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosisIvan Martinez-Forero, Ricardo Garcia-Munoz, Sara Martinez-Pasamar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myelomaOihana Murillo, Ainhoa Arina, Sandra Hervas-Stubbs, et al.
Plos One|January 4, 2013
Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapyMaria C Ochoa, Jessica Fioravanti, Erwin H Duitman, et al.
BMJ Oncology|February 25, 2026
First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumoursCarlos Gomez-Roca, Stéphane Champiat, Francois-Xavier Danlos, et al.
EMBO Molecular Medicine|November 21, 2019
Repurposing the yellow fever vaccine for intratumoral immunotherapyMaria Angela Aznar, Carmen Molina, Alvaro Teijeira, et al.
Cancer Discovery|October 24, 2015
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic CellsAlfonso R Sánchez-Paulete, Francisco J Cueto, María Martínez-López, et al.
Oncoimmunology|January 4, 2018
Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB)Arantza Azpilikueta, Elixabet Bolaños, Valerie Lang, et al.
Journal for Immunotherapy of Cancer|January 16, 2026
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumorsIgnacio Melero, Neeltje Steeghs, Ulrik Lassen, et al.
Pageof 34